Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research note issued on Tuesday,RTT News reports. They presently have a $40.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 80.18% from the company’s previous close. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

A number of other research firms have also weighed in on ORKA. Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research report on Thursday, October 31st. Lifesci Capital started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set an “outperform” rating and a $41.00 price target on the stock. TD Cowen assumed coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating for the company. Finally, Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Trading Down 0.4 %

NASDAQ ORKA opened at $22.20 on Tuesday. The company’s 50-day simple moving average is $26.50. Oruka Therapeutics has a 12-month low of $18.72 and a 12-month high of $53.88. The stock has a market capitalization of $26.86 million, a price-to-earnings ratio of -3.56 and a beta of 0.87.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ORKA. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter worth $343,000. The Manufacturers Life Insurance Company purchased a new stake in Oruka Therapeutics during the 3rd quarter valued at about $1,037,000. Wellington Management Group LLP bought a new stake in Oruka Therapeutics during the 3rd quarter valued at about $2,013,000. Janus Henderson Group PLC purchased a new position in Oruka Therapeutics in the third quarter worth about $5,840,000. Finally, Redmile Group LLC bought a new position in shares of Oruka Therapeutics in the third quarter worth approximately $10,091,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.